Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 02 2021
Historique:
received: 01 07 2020
revised: 27 08 2020
accepted: 18 11 2020
pubmed: 25 11 2020
medline: 21 1 2022
entrez: 24 11 2020
Statut: ppublish

Résumé

Desmoplastic small round cell tumor (DSRCT) is a highly lethal intra-abdominal sarcoma of adolescents and young adults. DSRCT harbors a t(11;22)(p13:q12) that generates the EWSR1-WT1 chimeric transcription factor, the key oncogenic driver of DSRCT. EWSR1-WT1 rewires global gene expression networks and activates aberrant expression of targets that together mediate oncogenesis. EWSR1-WT1 also activates a neural gene expression program. Among these neural markers, we found prominent expression of neurotrophic tyrosine kinase receptor 3 (NTRK3), a druggable receptor tyrosine kinase. We investigated the regulation of NTRK3 by EWSR1-WT1 and its potential as a therapeutic target We found that EWSR1-WT1 binds upstream of Our results indicate that EWSR1-WT1 directly activates NTRK3 expression in DSRCT cells, which are dependent on its expression and activity for growth. Pharmacologic inhibition of NTRK3 by entrectinib significantly reduces growth of DSRCT cells both

Identifiants

pubmed: 33229458
pii: 1078-0432.CCR-20-2585
doi: 10.1158/1078-0432.CCR-20-2585
pmc: PMC8212565
mid: NIHMS1649687
doi:

Substances chimiques

Benzamides 0
EWSR1 protein, human 0
Indazoles 0
NTRK3 protein, human 0
Oncogene Proteins, Fusion 0
RNA-Binding Protein EWS 0
WT1 Proteins 0
WT1 protein, human 0
Receptor, trkC EC 2.7.10.1
entrectinib L5ORF0AN1I

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1184-1194

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217694
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA222856
Pays : United States

Informations de copyright

©2020 American Association for Cancer Research.

Références

Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Cancer Res. 2014 Aug 15;74(16):4526-35
pubmed: 24934812
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28890946
Cancer Res. 1994 Jun 1;54(11):2837-40
pubmed: 8187063
Med Pediatr Oncol. 2002 Dec;39(6):547-51
pubmed: 12376975
Cancer Discov. 2018 Oct;8(10):1227-1236
pubmed: 30093503
PLoS One. 2008 Jun 04;3(6):e2353
pubmed: 18523561
Oncotarget. 2018 May 18;9(38):25206-25215
pubmed: 29861864
Cancer Discov. 2016 Jan;6(1):36-44
pubmed: 26546295
Future Oncol. 2015;11(7):1071-81
pubmed: 25804122
Cancer Genet Cytogenet. 1992 Dec;64(2):189-91
pubmed: 1486572
Pediatr Pathol. 1989;9(2):177-83
pubmed: 2473463
Oncogenesis. 2020 Apr 28;9(4):41
pubmed: 32345977
Eur J Surg Oncol. 2017 Feb;43(2):423-431
pubmed: 27890349
Mol Cancer Ther. 2016 Apr;15(4):628-39
pubmed: 26939704
Med Pediatr Oncol. 1999 Nov;33(5):500-3
pubmed: 10531577
Oncogene. 2018 Feb 8;37(6):798-809
pubmed: 29059150
Nat Genet. 1997 Nov;17(3):309-13
pubmed: 9354795
Oncotarget. 2015 Nov 17;6(36):39028-35
pubmed: 26472021
Pediatr Blood Cancer. 2020 Oct;67(10):e28559
pubmed: 32686305
J Biol Chem. 1996 Aug 9;271(32):19304-9
pubmed: 8702614
J Pathol. 2009 Jan;217(1):83-93
pubmed: 18855877
Sarcoma. 2008;2008:261589
pubmed: 18566684
J Biol Chem. 2010 May 7;285(19):14585-93
pubmed: 20220130
J Pathol. 2013 Apr;229(5):743-754
pubmed: 23288701
Am J Surg Pathol. 1991 Jun;15(6):499-513
pubmed: 1709557
Cancer Res. 2007 Feb 1;67(3):919-29
pubmed: 17283122
Mol Cancer Ther. 2018 Feb;17(2):455-463
pubmed: 29237803
Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1028-32
pubmed: 7862627
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):317-26
pubmed: 22104361
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Front Oncol. 2018 Feb 19;8:19
pubmed: 29515970
Sci Rep. 2020 Jul 23;10(1):12318
pubmed: 32703985
Clin Cancer Res. 2019 Aug 1;25(15):4712-4722
pubmed: 31028088
Clin Cancer Res. 2000 Sep;6(9):3522-9
pubmed: 10999739
Hum Pathol. 2004 Jun;35(6):711-21
pubmed: 15188137
J Clin Oncol. 1998 Sep;16(9):3028-36
pubmed: 9738572

Auteurs

Koichi Ogura (K)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Romel Somwar (R)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Julija Hmeljak (J)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Heather Magnan (H)

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.

Ryma Benayed (R)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Amir Momeni Boroujeni (A)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Anita S Bowman (AS)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Marissa S Mattar (MS)

Anti-tumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Inna Khodos (I)

Anti-tumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Elisa de Stanchina (E)

Anti-tumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Achim Jungbluth (A)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Marina Asher (M)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Igor Odintsov (I)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Alifiani B Hartono (AB)

Department of Pathology & Laboratory Medicine, Tulane University School of Medicine, New Orleans, Louisiana.

Michael P LaQuaglia (MP)

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.

Emily Slotkin (E)

Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.

Christine A Pratilas (CA)

Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

Sean Bong Lee (SB)

Department of Pathology & Laboratory Medicine, Tulane University School of Medicine, New Orleans, Louisiana.

Lee Spraggon (L)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Marc Ladanyi (M)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. ladanyim@mskcc.org.
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH